Market Intelligence, Clinical Progress, and High-Purity Reagents for Estrogen-Dependent Oncology and Endometriosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive enzymatic toolkit for HSD17B1 inhibitor discovery. Select your specificity and format below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Enzyme (WT) | HSD17B1 Recombinant Protein, full-length, N-terminus tagged. >95% purity (SDS-PAGE). Sequence verified. Theoretical MW 34.2 kDa. NADPH cofactor binding competent. | View HSD17B1 Products |
| Resistance Mutant Panel | HSD17B1 Mutant Variants (Y195F, S231A). Pre-emptive resistance profiling. Active site integrity preserved. High purity. | View HSD17B1 Products |
| Selectivity Counter-Screen | HSD17B2 & HSD17B3 Recombinant Proteins. Orthogonal SDR family members for specificity validation. Human and Cyno orthologs. Strict mass spec verification. | View HSD17B2 Products |
| Gene Delivery | HSD17B1 Lentivirus / Promise-ORF. Full-length ORF for stable cell line construction (MCF-7, T47D background). Puromycin selectable. | View HSD17B1 Products |
| Validator | HSD17B1 siRNA Set (3 unique sequences). For knockdown verification and assay specificity control. | View HSD17B1 Products |
| Benchmark Antibody | Anti-HSD17B1 Recombinant Antibody. Positive control for western blot and IHC. | View HSD17B1 Products |
| Pathway Partner A | CYP19A1 (Aromatase). Complementary estrogen synthesis target; combination therapy rationale. | View CYP19A1 Products |
| Pathway Partner B | STS (Steroid Sulfatase). Upstream estrogen precursor activation; alternative pathway blockade. | View STS Products |
| Related Target | ESR1 (ER-alpha). Downstream estrogen receptor for combination pathways and receptor crosstalk. | View ESR1 Products |
Critical Assay Challenges & TarMart Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Bidirectional Activity Confusion | HSD17B1 is strictly reductive (E1→E2, NADPH-dependent). TarMart provides cofactor-optimized enzyme preparations with confirmed NADPH binding affinity (theoretical Kd validation ready), clearly distinguishing from the oxidative HSD17B2. |
| Subfamily Selectivity Screening | Parallel availability of HSD17B2 (liver-protective) and HSD17B3 (androgen pathway) ortholog proteins with >95% purity for orthogonal counter-screens. Strict mass spec verification of identity. |
| Cellular Context Assay | Lentivirus particles (10^8 TU/mL) for stable integration into steroid-responsive breast cancer cell lines, enabling quantitative E2 production assays. |
| Resistance Mutation Pre-validation | Mutant protein library (active site variants Y195F, S231A) available for pre-emptive mechanism-of-resistance studies prior to clinical candidate selection. |
| Enzymatic Assay Standardization | High purity (>95%) recombinant enzymes expressed in optimal hosts with uniform theoretical MW, ensuring batch-to-batch consistency (CV<5%). |
| Lack of Controls | Recombinant benchmark antibodies and validated siRNA provided for assay standardization and specificity controls. |
| False Positives | Validated siRNA and orthogonal counter-screens (HSD17B2, HSD17B3) minimize false positive hits. |
Live HSD17B1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The HSD17B1 inhibitor landscape is transitioning from first-generation non-selective compounds to next-generation molecules with enhanced selectivity over HSD17B2 and HSD17B3. Major players such as Forendo Pharma (acquired by Organon) have advanced FOR-6219 into clinical trials for endometriosis, highlighting the shift from systemic hormonal suppression to localized estrogen modulation. As the understanding of intracrine estrogen synthesis in hormone-dependent cancers deepens, HSD17B1 is emerging as a critical node for local estrogen deprivation strategies, particularly for patients with acquired resistance to aromatase inhibitors. The next wave of R&D is targeting allosteric binding sites and tissue-specific delivery to spare hepatic HSD17B2 activity, alongside exploration of targeted degradation (PROTAC) approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Active Site) | AstraZeneca, Takeda, University of Bath spin-outs | ER+ Breast Cancer, Endometriosis | Enzymatic inhibition assay (NADPH consumption); need high-purity WT protein with confirmed cofactor binding |
| Small Molecule (Allosteric) | Academic consortia, Pre-clinical biotechs | Endometrial Cancer, Uterine Fibroids | Mutant Protein Panel (allosteric site validation); Selectivity panel vs HSD17B2/3 |
| Small Molecule (Endometriosis) | Forendo Pharma (Organon), Others | Endometriosis | Selectivity assay (need pure HSD17B1 and HSD17B2 proteins) |
| Combination Therapy | Oncology consortiums | Aromatase Inhibitor-resistant Breast Cancer | Cellular E2 Production Assay (need Lentivirus-stable cell lines) |
| Targeted Degraders (PROTAC) | Early Preclinical | Refractory Cancers | Degradation assay (need specific antibodies and cell lines) |